TriangleNCT03580655 · OUTCOME
Duration of Response (DOR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline through Month 65
What was measured
DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
Analysis population: Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by study steering committee review and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit.
Groups in this outcome
Avapritinib
Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.
| Group | Source count |
|---|---|
| Avapritinib | 61 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Avapritinib | 57.8 | Not reported | 46.1 | NA | Values were non-estimable (insufficient number of participants with events). |
Complete source fields
- classes
- categories
- measurements
- comment
- Values were non-estimable (insufficient number of participants with events).
- group Id
- OG000
- lower Limit
- 46.1
- upper Limit
- NA
- value
- 57.8
- denoms
- counts
- group Id
- OG000
- value
- 61
- units
- Participants
- description
- DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.
- id
- OG000
- title
- Avapritinib
- param Type
- MEDIAN
- population Description
- Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by study steering committee review and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit.
- reporting Status
- POSTED
- time Frame
- Baseline through Month 65
- title
- Duration of Response (DOR)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice